Roth Capital Keeps Lion Bio (LBIO) at 'Buy' Following Juno's (JUNO) ROCKET Study Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
SunTrust Robinson Humphrey Downgrades Juno Therapeutics (JUNO) to Hold
November 25, 2016 6:48 AM ESTSunTrust Robinson Humphrey downgraded Juno Therapeutics (NASDAQ: JUNO) from Buy to Hold with a price target of $25.00 (from $48.00) after the ROCKET study evaluating JCAR015 in no-option Adult ALL was placed on clinical hold for the second time.
The analyst sees reduced visibility and increased... More
Juno Therapeutics (JUNO) PT Lowered to $34 at Maxim Group
November 23, 2016 1:51 PM ESTMaxim Group analyst Jason McCarthy lowered his price target on Juno Therapeutics (NASDAQ: JUNO) to $34.00 (from $50.00) after the ROCKET study evaluating JCAR015 in no-option Adult ALL (Acute Lymphoblastic Leukemia) was placed on clinical hold for the second time. The firm maintained a Buy rating.
McCarthy highlighted:
The ROCKET study evaluating JCAR015 in no-option Adult ALL (Acute Lymphoblastic Leukemia) was placed on clinical hold for the second time. Two more patients died due to treatment-related neurotoxicity (cerebral edema), the same cause of death observed in July when ROCKET was... More